Jonathan Mitchell

Jonathan Mitchell focuses on hepatic immune-related adverse events at the University of Pennsylvania, where he has helped define the spectrum of liver toxicity associated with PD-1 and CTLA-4 blockade. He has developed management algorithms for steroid-refractory immune hepatitis, including the role of mycophenolate mofetil. His work has influenced ASCO and ESMO guidelines for hepatic irAE management.